Clinical Trials in San Antonio

Showing 9581-9600 of 14,633 trials

A Dose Escalation Study of MLN7243 (TAK-243) in Adult Participants With Advanced Solid Tumors

NCT02045095

The purpose of this study is to evaluate safety and tolerability (establish maximum tolerated dose \[MTD\], inform the recommended phase 2 dose \[RP2D\], and identify the dose-limiting toxicities \[DLTs\]) of MLN7243.

Advanced Malignant Solid Tumors

Millennium Pharmaceuticals, Inc.29 participantsStarted Jan 2014

Boston, Massachusetts, United States • St Louis, Missouri, United States • Cleveland, Ohio, United States +4 more locations

COMPLETEDPhase 1< 1 mile

Safety Tolerability, and PK of RYI-018 After Repeat Dosing in Subjects With Non-Alcoholic Fatty Liver Disease (NAFLD)

NCT03261739

BRB-018-001 is a multicenter, adaptive design, randomized, parallel group study to evaluate the safety, tolerability, and PK of repeat IV doses of RYI-018 in subjects with NAFLD.

NAFLD

Bird Rock Bio, Inc.84 participantsStarted Aug 2017

Chula Vista, California, United States • Miami, Florida, United States • Orlando, Florida, United States +3 more locations

COMPLETEDPhase 2< 1 mile

A Phase 2, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of PF-00489791 In Patients With Type 2 Diabetes And Overt Nephropathy

NCT01200394

PF-00489791 is an inhibitor of phosphodiesterase type 5. Our hypothesis is that PF-00489791 will enhance the relaxation of blood vessels within the kidney and so reduce blood pressure, improving renal function.

Diabetic Nephropathies

Pfizer256 participantsStarted Dec 2010

Huntsville, Alabama, United States • Huntsville, Alabama, United States • Glendale, Arizona, United States +157 more locations

A Dose Escalation Study of MLN7243 (TAK-243) in Adult Participants With Advanced Solid Tumors

Safety Tolerability, and PK of RYI-018 After Repeat Dosing in Subjects With Non-Alcoholic Fatty Liver Disease (NAFLD)

A Phase 2, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of PF-00489791 In Patients With Type 2 Diabetes And Overt Nephropathy

Find Trials by Condition in San Antonio

Study of Itacitinib in Combination With Corticosteroids for the Treatment of Acute GVHD

A Study Exploring the Safety, Tolerability, and Efficacy of a 28 Day Course Followed by an Additional 56 Day Course of Itacitinib in Subjects With Active Rheumatoid Arthritis

A Study to Evaluate ITCA 650 for the Treatment of Type 2 Diabetes in Patients With High Baseline HbA1c

Quality of Life and Care Needs of Patients With Persistent or Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Peritoneal Cancer

Safety and Efficacy of Preoperative Antithrombin Supplementation in Patients Undergoing High-Risk Cardiopulmonary Bypass

Rate Control Versus Rhythm Control For Postoperative Atrial Fibrillation

Study of Orally Administered AG-881 in Patients With Advanced Hematologic Malignancies With an IDH1 and/or IDH2 Mutation

Edoxaban vs. Warfarin in Subjects Undergoing Cardioversion of Nonvalvular Atrial Fibrillation (NVAF)

A Dose Range Finding Study of JNJ-38518168 in Patients With Active Rheumatoid Arthritis in Spite of Treatment With Methotrexate

Driveline Silicone Skin Interface Registry

CRT Implant Strategy Using the Longest Electrical Delay for Non-left Bundle Branch Block Patients

Study to Evaluate Efficacy of CO-1.01 as Second Line Therapy for Gemcitabine-Refractory Stage IV Pancreatic Adenocarcinoma

An Efficacy and Safety Study of Ustekinumab in Participants With Active Nonradiographic Axial Spondyloarthritis

A Study of LY2928057 in Hemodialysis Participants

A Study of Ixekizumab in Participants With Plaque Psoriasis

Open-Label Study of Asfotase Alfa in Infants and Children ≤ 5 Years of Age With Hypophosphatasia (HPP)

Dating Matters: Strategies to Promote Healthy Teen Relationships